As a leader in the CRDMO sector, WuXi STA is no stranger to breaking new grounds. The company’s latest move is the launch of a high potency (HP), fully automated sterile injectable manufacturing line in Wuxi City, China. This facility, designed to meet the growing demand for high potency pharmaceuticals, can produce an impressive 12 million units per year.
With this launch, WuXi STA reiterates its commitment to strict compliance with international quality and safety standards. The new manufacturing line follows the International Society for Pharmaceutical Engineering (ISPE) guidelines, ensuring the integrity of the sealed isolators. It’s equipped with an independent air conditioning system and a bag-in bag-out (BIBO) exhaust air purification system, prioritizing operator safety and environmental protection.
The company has also revealed plans for expansion. WuXi STA intends to add two more injectable manufacturing lines at the Wuxi City site by 2024. This strategy will undoubtedly cement its place as a CRDMO leader and an enabler of innovation in the pharmaceutical industry. As stated by Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, WuXi STA is “committed to accelerating pharmaceutical development and bringing new therapeutics for patients worldwide.”